December 9, 2011 — Voting in favor of the norelgestromin/ethinyl estradiol transdermal contraceptive patch (Ortho Evra, Jannsen), a US Food and Drug Administration (FDA) advisory panel today ...

Nov. 11, 2005 — The U.S. Food and Drug Administration (FDA) approved new labeling today regarding the increased level of estrogen exposure associated with use of an ethinyl estradiol/norelgestromin ...

PITTSBURGH, April 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE™ (Norelgestromin / Ethinyl Estradiol ...

The patch supplies norelgestromin and ethinyl estradiol to the bloodstream through the skin. Has any evidence of genital swelling been documented with the use of the patch when placed inappropriately?

The labeling for Ortho Evra (norelgestromin/ethinyl estradiol transdermal patch, from Ortho-McNeil) has been updated to include additional safety data regarding an increased risk of venous ...

The U.S. Food and Drug Administration approved additional changes to the Ortho Evra Contraceptive Transdermal (Skin) Patch label to include the results of a new epidemiology study that found that ...

Mylan MYL today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE™ (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day), the generic version ...